Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery

Movement Disorders

Volumn 15, Issue 3, 2000, Pages 467-473

  Montgomery Jr , Erwin B ^a   Koller, William C ^b   LaMantia, Theodora J K ^a   Newman, Mary C ^c   Swanson Hyland, Elizabeth ^d   Kaszniak, Alfred W ^c   Lyons, Kelly ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c University of Arizona   (United States)

^d Responsive Health Care   (United States)

Author keywords

Diagnosis; Mood; Movement; Olfaction; Parkinson's disease

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; HUMAN; IDIOPATHIC DISEASE; JOINT FUNCTION; MAJOR CLINICAL STUDY; MALE; MOOD; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SMELLING; VELOCITY; WRIST;

EID: 0342906195     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200005)15:3<467::aid-mds1007>3.0.co;2-%23     Document Type: Article

References (29)

1. Tetrud JW, Langston JW. The effects of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-522.
2. The Parkinson Study Group. Effects of tocopherol and deprenyl in Parkinson's disease. N Engl J Med 1993;328:176-183.
3. Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.
4. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
5. Berger BD, Wise CD, Stein L. Nerve growth factor: enhanced recovery of feeding after hypothalamic damage. Science 1973;185: 506-508.
6. Date L, Notter MFD, Felten SY, Felten DL. Stereotaxic injections of Gdla ganglioside induces limited recovery of striatal dopaminergic system in MPTP-treated aging mice. J Neurosci Res 1991; 28:525-530.
7. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules: applications and methodological standards. N Engl J Med 1985;313:793-799.
8. Montgomery EB Jr, Gorman D, Nuessen J. Motor initiation versus execution in normal and Parkinson's disease subjects. Neurology 1991;41:1469-1475.
9. Montgomery EB, Nuessen J, Gorman D. Reaction time and movement velocity abnormalities in Parkinson's disease under different task conditions. Neurology 1991;41:1476-1481.
10. Patrick HT, Levy DM. Parkinson's disease: a clinical study of 146 cases. Arch Neurol Psychiatry 1922;7:711-720.
11. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 1983;33:943-946.
12. Doty RL, Newhouse MG, Azalina JD. Internal consistency and short-term test-retest reliability of the University of Pennsylvania Smell Identification Test. Chem Senses 1985;33:943-946.
13. Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson's disease. J Neurol Neurosurg Psychiatry 1987;50:88-89.
14. Doty RL, Perl DP, Steele JC, et al. Olfactory dysfunction in three neurodegenerative diseases. Geriatrics 1991;46:47-51.
15. Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Diseases of the Nervous System 1972;33:577-583.
16. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-389.
17. Brown GL, Wilson WP. Parkinsomism and depression. South Med J 1972;33:577-583.
18. Mayeux R, Stem Y, Rosen J, Leventhal I. Depression, intellectual impairment and Parkinson's disease. Neurology 1981;31:645-650.
19. Mayeux R, Williams JBW, Stem Y, Cote L. Depression and Parkinson's disease. Adv Neurol 1984;40:235-240.
20. Doty RL, Golbe LI, McKeown DA, et al. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993;43:962-965.
21. Doty RL. The Smell Identification Test Administration Manual. Haddon Heights, NJ: Sensonics, Inc, 1983.
22. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-571.
23. Gallagher D, Brenkenridge J, Steinmetz J, Thompson LW. The Beck Depression Inventory and research diagnostic criteria: congruence in an older population. J Consult Clin Psychol 1983;51: 945-951.
24. Jacobs KW, Boze MM. Correlations among scales of the Beck Depression Inventory and the profile of mood states. Psychol Rep 1993;73:431-434.
25. Leahy JM. Validity and reliability of the Beck Depression Inventory-short form in a group of bereaved females. J Clin Psychol 1992;48:64-68.
26. Stevens J. Applied Multivariate Statistics for the Social Sciences, 2nd ed. Montvale, NJ: Lawrence Erlbaum Associates, 1992.
27. Montgomery EB Jr, Lyons K, Koller WC. Early detection of or risk for Parkinson's disease. II: a prospective study. Mov Disord. In press.
28. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35:841-845.
29. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsomsm: a door-to-door survey in three Sicilian municipalities. Neurology 1992;42:1901-1907.